MacroGenics (MGNX) vs Protalix BioTherapeutics (DE) (PLX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
MacroGenics (MGNX) has outperformed Protalix BioTherapeutics (DE) (PLX) over the past year, gaining 106.4% versus a gain of 8.4%. Over five years, PLX leads with a +120.3% price change compared with -82.0% for MGNX. MacroGenics is the larger company by market cap ($220.1 million vs $216.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MGNX | PLX |
|---|---|---|
| Share price | $3.46 | $2.69 |
| Market cap | $220.08M | $216.74M |
| 1-day change | -2.68% | -0.74% |
| YTD return | +120.50% | +50.56% |
| 1-year return | +106.40% | +8.40% |
| 5-year return | -82.02% | +120.33% |
| P/E ratio (TTM) | — | 11.70 |
| Forward P/E | — | 4.34 |
| EPS (TTM) | $-1.70 | $0.23 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.08 | $3.19 |
| 52-week low | $1.29 | $1.60 |
| Distance from 52-week high | -31.99% | -15.67% |
| Analyst consensus | buy | none |
| Avg. price target upside | +131.55% | +308.92% |
| Average volume | 621.73K | 732.64K |
| Shares outstanding | 63.70M | 80.57M |
| Employees | 293 | 226 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MGNX has outperformed PLX by 98.0 percentage points over the past year.
About MacroGenics
MGNX stock →MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials.
Health Care · Biotechnology: Pharmaceutical Preparations · 293 employees
About Protalix BioTherapeutics (DE)
PLX stock →Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 226 employees
MGNX vs PLX FAQ
Which is bigger, MacroGenics or Protalix BioTherapeutics (DE)?
MacroGenics (MGNX) is larger, with a market capitalization of $220.08M compared with $216.74M for Protalix BioTherapeutics (DE) (PLX).
Which stock has performed better over the past year, MGNX or PLX?
MGNX returned +106.40% over the past 12 months, compared with +8.40% for PLX (price return, excluding dividends). Past performance does not predict future results.
Are MacroGenics and Protalix BioTherapeutics (DE) in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for MacroGenics and Biotechnology: Biological Products (No Diagnostic Substances) for Protalix BioTherapeutics (DE).